109 related articles for article (PubMed ID: 36368126)
1. Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family.
Agaoglu NB; Ng OH; Unal B; Dogan OA; Amanvermez U; Yildiz J; Doganay L; Ghazani AA; Rana HQ
Cancer Genet; 2022 Nov; 268-269():128-136. PubMed ID: 36368126
[TBL] [Abstract][Full Text] [Related]
2. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
[TBL] [Abstract][Full Text] [Related]
3. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
4. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
5. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026
[TBL] [Abstract][Full Text] [Related]
6. Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center.
Poliani L; Greco L; Barile M; Dal Buono A; Bianchi P; Basso G; Giatti V; Genuardi M; Malesci A; Laghi L;
ESMO Open; 2022 Dec; 7(6):100607. PubMed ID: 36356413
[TBL] [Abstract][Full Text] [Related]
7. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
8. Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel.
AlHarbi M; Mobark NA; AlJabarat WAR; ElBardis H; AlSolme E; Hamdan AB; AlFakeeh AH; AlMushawah F; AlHarthi F; AlSharm AA; Balbaid AAO; AlJohani N; Zhou AY; Robinson HA; Alqahtani SA; Abedalthagafi M
Oncotarget; 2023 Jun; 14():580-594. PubMed ID: 37306523
[TBL] [Abstract][Full Text] [Related]
9. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
11. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
12. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
13. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
14. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
[TBL] [Abstract][Full Text] [Related]
15. Concurrent pathogenic variations in patients with hereditary cancer syndromes.
Agaoglu NB; Doganay L
Eur J Med Genet; 2021 Dec; 64(12):104366. PubMed ID: 34637943
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
17. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
[TBL] [Abstract][Full Text] [Related]
18. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
[TBL] [Abstract][Full Text] [Related]
19. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
20. Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
Dutil J; Teer JK; Golubeva V; Yoder S; Tong WL; Arroyo N; Karam R; Echenique M; Matta JL; Monteiro AN
Sci Rep; 2019 Nov; 9(1):17769. PubMed ID: 31780696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
